Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 242

1.

Patient satisfaction with alosetron for the treatment of women with diarrhea-predominant irritable bowel syndrome.

Olden K, DeGarmo RG, Jhingran P, Bagby B, Decker C, Markowitz M, Carter E, Bobbitt W, Dahdul A, DeCastro E, Gringeri L, Johanson J, Levinson L, Mula G, Poleynard G, Stoltz RR, Truesdale R, Young D; Lotronex Investigator Team..

Am J Gastroenterol. 2002 Dec;97(12):3139-46.

PMID:
12492201
2.

A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome.

Camilleri M, Chey WY, Mayer EA, Northcutt AR, Heath A, Dukes GE, McSorley D, Mangel AM.

Arch Intern Med. 2001 Jul 23;161(14):1733-40.

PMID:
11485506
3.

Long-term safety and efficacy of alosetron in women with severe diarrhea-predominant irritable bowel syndrome.

Chey WD, Chey WY, Heath AT, Dukes GE, Carter EG, Northcutt A, Ameen VZ.

Am J Gastroenterol. 2004 Nov;99(11):2195-203.

PMID:
15555002
4.

Effect of alosetron on bowel urgency and global symptoms in women with severe, diarrhea-predominant irritable bowel syndrome: analysis of two controlled trials.

Lembo AJ, Olden KW, Ameen VZ, Gordon SL, Heath AT, Carter EG.

Clin Gastroenterol Hepatol. 2004 Aug;2(8):675-82.

PMID:
15290660
5.

Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome.

Lembo T, Wright RA, Bagby B, Decker C, Gordon S, Jhingran P, Carter E; Lotronex Investigator Team..

Am J Gastroenterol. 2001 Sep;96(9):2662-70.

PMID:
11569692
6.

A randomized, double-blind, placebo-controlled study to assess efficacy and safety of 0.5 mg and 1 mg alosetron in women with severe diarrhea-predominant IBS.

Krause R, Ameen V, Gordon SH, West M, Heath AT, Perschy T, Carter EG.

Am J Gastroenterol. 2007 Aug;102(8):1709-19. Epub 2007 May 17.

PMID:
17509028
7.
8.

Alosetron improves quality of life in women with diarrhea-predominant irritable bowel syndrome.

Watson ME, Lacey L, Kong S, Northcutt AR, McSorley D, Hahn B, Mangel AW.

Am J Gastroenterol. 2001 Feb;96(2):455-9.

PMID:
11232690
9.

A dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS.

Chang L, Ameen VZ, Dukes GE, McSorley DJ, Carter EG, Mayer EA.

Am J Gastroenterol. 2005 Jan;100(1):115-23.

PMID:
15654790
10.

Tolerability and safety of alosetron during long-term administration in female and male irritable bowel syndrome patients.

Wolfe SG, Chey WY, Washington MK, Harding J, Heath AT, McSorley DJ, Dukes GE, Hunt CM.

Am J Gastroenterol. 2001 Mar;96(3):803-11.

PMID:
11280555
11.

Symptomatic efficacy of beidellitic montmorillonite in irritable bowel syndrome: a randomized, controlled trial.

Ducrotte P, Dapoigny M, Bonaz B, Siproudhis L.

Aliment Pharmacol Ther. 2005 Feb 15;21(4):435-44.

12.

Efficacy of alosetron in irritable bowel syndrome: a meta-analysis of randomized controlled trials.

Cremonini F, Delgado-Aros S, Camilleri M.

Neurogastroenterol Motil. 2003 Feb;15(1):79-86.

13.

Alosetron relieves pain and improves bowel function compared with mebeverine in female nonconstipated irritable bowel syndrome patients.

Jones RH, Holtmann G, Rodrigo L, Ehsanullah RS, Crompton PM, Jacques LA, Mills JG.

Aliment Pharmacol Ther. 1999 Nov;13(11):1419-27.

14.

Effects of alosetron on gastrointestinal transit time and rectal sensation in patients with irritable bowel syndrome.

Thumshirn M, Coulie B, Camilleri M, Zinsmeister AR, Burton DD, Van Dyke C.

Aliment Pharmacol Ther. 2000 Jul;14(7):869-78.

15.

A double-blind, randomized, placebo-controlled dose-ranging study to evaluate the efficacy of alosetron in the treatment of irritable bowel syndrome.

Bardhan KD, Bodemar G, Geldof H, Schütz E, Heath A, Mills JG, Jacques LA.

Aliment Pharmacol Ther. 2000 Jan;14(1):23-34.

16.

Tegaserod for female patients suffering from IBS with mixed bowel habits or constipation: a randomized controlled trial.

Chey WD, Paré P, Viegas A, Ligozio G, Shetzline MA.

Am J Gastroenterol. 2008 May;103(5):1217-25. doi: 10.1111/j.1572-0241.2008.01808.x.

17.

Platelet serotonin transporter in patients with diarrhea-predominant irritable bowel syndrome both before and after treatment with alosetron.

Bellini M, Rappelli L, Blandizzi C, Costa F, Stasi C, Colucci R, Giannaccini G, Marazziti D, Betti L, Baroni S, Mumolo MG, Marchi S, Del Tacca M.

Am J Gastroenterol. 2003 Dec;98(12):2705-11.

PMID:
14687821
18.

Safety, tolerability and satisfaction with tegaserod therapy in Asia-Pacific patients with irritable bowel syndrome with constipation.

Fock KM, Wagner A; Asia Pacific Gastroenterology Group..

J Gastroenterol Hepatol. 2007 Aug;22(8):1190-8. Epub 2007 May 24.

PMID:
17524039
19.

Effect of alosetron on responses to colonic distension in patients with irritable bowel syndrome.

Delvaux M, Louvel D, Mamet JP, Campos-Oriola R, Frexinos J.

Aliment Pharmacol Ther. 1998 Sep;12(9):849-55.

20.

Evaluation of treatment continuation with alosetron by IBS-D severity criteria.

Nicandro JP, Shin P, Chuang E.

Curr Med Res Opin. 2012 Mar;28(3):449-56. doi: 10.1185/03007995.2011.653435. Epub 2012 Feb 7.

PMID:
22313141

Supplemental Content

Support Center